Vir Biotechnology names Aziz Sawaf CFO effective October 5, 2026

Vir Biotechnology, Inc.

Vir named Aziz Sawaf EVP and CFO effective Oct. 5, 2026; Brent Sabatini ceases as interim principal financial officer, staying as SVP/Chief Accounting Officer.
Sawaf, Theravance CFO since 2023 and ex-Gilead finance, gets $520,000 base salary, 45% target bonus, $150,000 sign-on.
Equity grant around Nov. 15, 2026 includes options for 150,000 shares and 75,000 RSUs, each vesting over four years; option vests 25% on first anniversary then monthly.
Under Vir's severance plan, a covered termination during the 12-month post-change-in-control period gives 12 months' salary plus target bonus, health benefits, and full equity acceleration.
Outside that period, severance is nine months' salary plus pro-rated target bonus and up to nine months of health benefits.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.